Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.

The global Long-acting Injectable Antipsychotics (LAIs) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Long-acting Injectable Antipsychotics (LAIs) Industry Forecast” looks at past sales and reviews total world Long-acting Injectable Antipsychotics (LAIs) sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Injectable Antipsychotics (LAIs) sales for 2024 through 2030.

• With Long-acting Injectable Antipsychotics (LAIs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Injectable Antipsychotics (LAIs) industry.

This Insight Report provides a comprehensive analysis of the global Long-acting Injectable Antipsychotics (LAIs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyzes the strategies of leading global companies with a focus on Long-acting Injectable Antipsychotics (LAIs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Injectable Antipsychotics (LAIs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Injectable Antipsychotics (LAIs) and breaks down the forecast by:

• Type
• Application
• Geography
• Market size

to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Injectable Antipsychotics (LAIs).

The United States market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

The China market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

The Europe market for Long-acting Injectable Antipsychotics (LAIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Long-acting Injectable Antipsychotics (LAIs) players cover:

• Otsuka Pharmaceutical
• CHEPLAPHARM Arzneimittel GmbH
• Alkermes Pharma Ireland Limited
• Essential Pharma
• Janssen Pharmaceuticals

In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Injectable Antipsychotics (LAIs) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• First-generation
• Second-generation

Segmentation by Application:

• Schizophrenia
• Bipolar Disorder
• Other

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Otsuka Pharmaceutical
• CHEPLAPHARM Arzneimittel GmbH
• Alkermes Pharma Ireland Limited
• Essential Pharma
• Janssen Pharmaceuticals
• Indivior UK Limited
• Qilu Pharmaceutical
• Lvye Pharmaceutical

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Long-acting Injectable Antipsychotics (LAIs) market?
2. What factors are driving Long-acting Injectable Antipsychotics (LAIs) market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Long-acting Injectable Antipsychotics (LAIs) market opportunities vary by end market size?
5. How does Long-acting Injectable Antipsychotics (LAIs) break out by Type, by Application?